J.B. Chemicals & Pharmaceuticals, established in 1976, is one of the fastest-growing pharmaceutical companies in India and a leading player in the hypertension and the heart-failure segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. The company exports its finished formulations to many countries. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. It has several state-of-the-art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

The company has a leading global position in the contract development and manufacturing (CDMO) of medicated lozenges driven by marquee client relationships. The CDMO business provides a great opportunity for growth. The organisation is currently ranked among the top 5 manufacturers of lozenges globally and boasts of some big consumer health/ FMCG companies.

JB Pharma is one of the few Indian companies to successfully implement Osmotic Release Technology for some of its medicines. This technology is an advanced controlled-release oral drug delivery system in the form of a rigid tablet with a semi-permeable outer membrane and a small, laser-drilled hole in it. It is built for a sustained release of the drug over 24 hours.

Business area of the company

J. B. Chemicals & Pharmaceuticals is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs). 

The company’s core therapies

Cardiology: The company emphasis on heart failure, hypertension and lipid management therapies continue to be a significant contributor in shaping the cardiology market in India 

Nephrology: JB’s commitment to nephro-protection includes public awareness initiatives, accurate diagnostic tests like micral tests and novel molecules for treatment.

Paediatrics: JB’s child health range of products offers effective yet gentle solutions for aiding digestion and sleep, fortifying nutrition to combatting infections and soothing diaper rashes.

Respiratory: JB’s commitment to lung health spans across treatments for allergies, asthma, COPD, lower respiratory tract & viral infections and interstitial lung disease.

Gastroenterology: JB is a pioneer in gastroenterology and has a diverse and comprehensive portfolio, which includes proton-pump inhibitors, pro-kinetics, antacids, laxatives and probiotics in various dosage forms.

Gynaecology: JB plays a vital role in reproductive health with a wide range of treatments for infertility, anaemia, hormonal balance and pregnancy care. Through its quality hormones (IVF), it partner with millions of couples in their journey towards a fuller life.

Dental: The company’s comprehensive treatments for ulcers, pain and infections ensure good oral health and happy expressions.

Wound Care: JB's wound care portfolio offers products for treating both acute wounds with urgency and chronic wounds with patience.

Ophthalmology: The company’s newest ophthalmology portfolio offers anti-infectives, antiglaucoma, NSAIDs and tear substitute drugs.

Milestones 

• 1976: 1st brick in the foundation laid by late J.B. Mody by incorporating JB Chemicals & Pharmaceuticals Laboratories (JBCPL).

• 1977: Introduced the product Metrogyl, that went on to become the ‘gold standard’ in the industry.

• 1980: Forayed into the cardiac segment with the revolutionary product Nicardia.

• 1985: Got publicly listed and expanded from API to Formulations.

• 1989: Iconic product Rantac introduced.

• 2000: Capitalized on the vast Russia & CIS OT market with 2 Brands: Doktor Mom & Rinza.

• 2003: Received first FDA approval for our Panoli Plant:T10.

• 2007: Launched the product Cilacar that went on to become a leading brand in cardiology and nephrology.

• 2008: Made a strategic investment in a company in South Africa called Biotech Laboratories.

• 2016: Received a silver award from the United States Pharmacopeia (USP) for participation in the Monograph Development & Upgradation Program and preparation and distribution of USP reference substance.

• 2020: Leading private equity firm Kohlberg Kravis Roberts & Co. Inc. (KKR), acquired a controlling stake of JBCPL.

• 2021: Ranked 28th in the Industry (ORG- IMS) with 5 brands: Rantac (Anti – Peptic Ulcer ant), Metrogyl (Amebicides), Nicardia ( Calcium Channel Blocker) and Cilacar-T featuring in top 300 brands of the Indian pharmaceutical market.

• 2022: Acquisition of Azmarda and Sanzyme.

• 2022: Launch of New JB identity.

• 2023: 6 brands in top 300 IPM brands as per IQVIA.

• 2023: Fastest growing company among the top 10 players in the cardiology segment.

• 2024-25: Five of JB Pharma’s flagship brands now feature among the top 150 brands in the Indian Pharmaceutical Market (IPM). 

• 2024-25: Sporlac has made its way into the top 300 brands, marking a significant milestone in its growth journey.

• 2024-25: Torrent Pharmaceuticals has entered into definitive agreements to acquire a controlling stake in JB Pharma from KKR.